688266.SH
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 87.79
−6.61%Year over year
Reported trailing growth
- Revenue
- +161.4%
- EBITDA
- —
- EBIT
- +454.5%
- EPS
- +490.4%
- Free cash flow
- +505.1%
- Operating cash flow
- +1527.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +38.9%
- EBITDA
- -13.2%
- EBIT
- -8.4%
- Net income
- -18.2%
- EPS
- -19.2%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026